JP2023506779A - 慢性移植片対宿主病の処置用抗体 - Google Patents

慢性移植片対宿主病の処置用抗体 Download PDF

Info

Publication number
JP2023506779A
JP2023506779A JP2022535607A JP2022535607A JP2023506779A JP 2023506779 A JP2023506779 A JP 2023506779A JP 2022535607 A JP2022535607 A JP 2022535607A JP 2022535607 A JP2022535607 A JP 2022535607A JP 2023506779 A JP2023506779 A JP 2023506779A
Authority
JP
Japan
Prior art keywords
csf
antibody
versus
host disease
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022535607A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023506779A5 (https=
Inventor
オルデントリヒ，ピーター
マイヤーズ，マイケル
モリソン，ブリッグス・ダブリュー
Original Assignee
シンダックス ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シンダックス ファーマシューティカルズ， インコーポレイテッド filed Critical シンダックス ファーマシューティカルズ， インコーポレイテッド
Publication of JP2023506779A publication Critical patent/JP2023506779A/ja
Publication of JP2023506779A5 publication Critical patent/JP2023506779A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022535607A 2019-12-09 2020-12-09 慢性移植片対宿主病の処置用抗体 Pending JP2023506779A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962945842P 2019-12-09 2019-12-09
US62/945,842 2019-12-09
US202063110111P 2020-11-05 2020-11-05
US63/110,111 2020-11-05
PCT/US2020/064010 WO2021119128A1 (en) 2019-12-09 2020-12-09 Antibodies for the treatment of chronic graft versus host disease

Publications (2)

Publication Number Publication Date
JP2023506779A true JP2023506779A (ja) 2023-02-20
JP2023506779A5 JP2023506779A5 (https=) 2023-12-13

Family

ID=76330540

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022535607A Pending JP2023506779A (ja) 2019-12-09 2020-12-09 慢性移植片対宿主病の処置用抗体

Country Status (11)

Country Link
US (1) US12552869B2 (https=)
EP (1) EP4073100A4 (https=)
JP (1) JP2023506779A (https=)
KR (1) KR20220123004A (https=)
CN (1) CN115298210A (https=)
AU (1) AU2020401551A1 (https=)
CA (1) CA3164126A1 (https=)
IL (1) IL293705A (https=)
MX (1) MX2022007029A (https=)
PH (1) PH12022551401A1 (https=)
WO (1) WO2021119128A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260013464A (ko) * 2023-05-17 2026-01-28 신닥스 파마슈티컬스, 인크. 항-콜로니 자극 인자 1 수용체 항체를 이용한 만성 이식편대숙주 질환-관련 폐쇄성 세기관지염 증후군의 치료 방법
CN121620392A (zh) * 2023-07-23 2026-03-06 因赛特公司 使用抗集落刺激因子1受体抗体治疗慢性移植物抗宿主病的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008526773A (ja) * 2004-12-30 2008-07-24 ドール バイオファーマ、インコーポレイテッド ベクロメタゾンジプロピオネート及びプレドニゾンでの、移植片対宿主病及び白血病の治療
JP2016529266A (ja) * 2013-08-30 2016-09-23 ユーシービー バイオファルマ エスピーアールエル 抗体

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
WO2007142667A2 (en) 2005-10-13 2007-12-13 Human Genome Sciences, Inc. Treatment of patients with autoantibody positive disease
EP2076266A2 (en) 2006-05-31 2009-07-08 The Board of Trustees of the Leland Stanford Junior University Method of treating inflammatory diseases using tyroskine kinase inhibitors
WO2008055013A2 (en) 2006-10-31 2008-05-08 Janssen Pharmaceutica N.V. 5-oxo-5,8 - dihydro - pyrido - pyrimidines as inhibitors of c-fms kinase
PL2188313T3 (pl) 2007-08-21 2018-04-30 Amgen, Inc. Białka wiążące ludzki antygen c-fms
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
US20090148905A1 (en) 2007-11-30 2009-06-11 Claire Ashman Antigen-binding constructs
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
BRPI0909044B8 (pt) 2008-03-14 2021-05-25 Transgene Sa anticorpo que se liga especificamente ao csf-1r humano,composição farmacêutica e uso dos mesmos
WO2010012667A1 (en) 2008-08-01 2010-02-04 Santaris Pharma A/S Micro-rna mediated modulation of colony stimulating factors
ES2722300T3 (es) 2009-12-10 2019-08-09 Hoffmann La Roche Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
US9169323B2 (en) 2010-03-05 2015-10-27 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
JP5989547B2 (ja) 2010-03-05 2016-09-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトｃｓｆ−１ｒに対する抗体及びその使用
EP2545078A1 (en) 2010-03-11 2013-01-16 UCB Pharma, S.A. Pd-1 antibody
AR080698A1 (es) 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
HRP20190047T1 (hr) 2010-05-04 2019-02-22 Five Prime Therapeutics, Inc. Protutijela koja se vežu na csf1r
UA112425C2 (uk) 2010-12-13 2016-09-12 Еррей Біофарма Інк. ЗАМІЩЕНІ N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗО[1,2-a]ПІРИДИН-3-КАРБОКСАМІДНІ СПОЛУКИ ЯК ІНГІБІТОРИ РЕЦЕПТОРНОЇ ТИРОЗИНКІНАЗИ ІІІ ТИПУ
WO2013057281A2 (en) 2011-10-21 2013-04-25 Transgene Sa Modulation of macrophage activation
RU2658603C2 (ru) 2011-12-15 2018-06-21 Ф.Хоффманн-Ля Рош Аг Антитела против человеческого csf-1r и их применения
KR20140127855A (ko) 2012-02-06 2014-11-04 제넨테크, 인크. Csf1r 억제제를 사용하는 조성물 및 방법
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
GB201315486D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
ES2763309T3 (es) 2015-02-09 2020-05-28 UCB Biopharma SRL Formulación farmacéutica que comprende anticuerpos
CN111278459A (zh) * 2017-05-19 2020-06-12 赛达克斯制药股份有限公司 组合疗法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008526773A (ja) * 2004-12-30 2008-07-24 ドール バイオファーマ、インコーポレイテッド ベクロメタゾンジプロピオネート及びプレドニゾンでの、移植片対宿主病及び白血病の治療
JP2016529266A (ja) * 2013-08-30 2016-09-23 ユーシービー バイオファルマ エスピーアールエル 抗体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"NCT03604692A Phase 1 Study to Evaluate SNDX- 6352 in Subjects With Active cGVHD", CLINICALTRIALS.GOV, JPN6024047194, 4 December 2019 (2019-12-04), ISSN: 0005668608 *
J. CLIN. INVEST., vol. vol.124, issue 10, JPN6024047195, 2014, pages 4266 - 4280, ISSN: 0005668607 *

Also Published As

Publication number Publication date
EP4073100A1 (en) 2022-10-19
KR20220123004A (ko) 2022-09-05
US12552869B2 (en) 2026-02-17
PH12022551401A1 (en) 2023-08-23
IL293705A (en) 2022-08-01
WO2021119128A1 (en) 2021-06-17
MX2022007029A (es) 2022-08-15
CA3164126A1 (en) 2021-06-17
AU2020401551A1 (en) 2022-06-30
EP4073100A4 (en) 2024-02-14
CN115298210A (zh) 2022-11-04
US20230035183A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
JP2024038250A (ja) 抗ｐｄ－１抗体及び抗ｃｔｌａ４抗体によるがんの処置方法
CN118924895A (zh) 用于癌症治疗的结合her2、nkg2d和cd16的多特异性结合蛋白的药物制剂和剂量方案
WO2022187539A1 (en) Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
CN103189074A (zh) 使用il-17拮抗剂治疗类风湿性关节炎的方法
CN106413751A (zh) 用于治疗癌症的抗ccr4抗体和4‑1bb激动剂的组合
TW202237184A (zh) 抗cd19組合療法
CN109963577A (zh) 用于通过施用il-4r抑制剂治疗严重特应性皮炎的方法
US20230131598A1 (en) Combination treatment for cancer
JP2024156880A (ja) がんを処置するための抗ｌａｇ３抗体の投薬レジメンおよび抗ｐｄ－１抗体との組み合わせ治療
CN115443152A (zh) 使用pd-1拮抗剂、ctla4拮抗剂以及仑伐替尼或其药学上可接受的盐的组合治疗癌症的方法
US20230140694A1 (en) Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies
JP2023506779A (ja) 慢性移植片対宿主病の処置用抗体
US20230149543A1 (en) Combination treatment for cancer based upon an icos antbody and a pd-l1 antibody tgf-bets-receptor fusion protein
TW202502813A (zh) 包含偶聯物的藥物組合的治療方法和用途
WO2015191760A2 (en) Compositions and methods for treating rheumatoid arthritis
WO2025036445A1 (en) Treatment of lung cancer with anti-pd-1 and chemotherapy
EA052089B1 (ru) Антитела для лечения хронического заболевания "трансплантат против хозяина"
HK40110052A (zh) 用於治疗癌症的方法和组合物
JP2023504679A (ja) インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して扁平苔癬を治療する方法
CN117940452A (zh) 用于治疗癌症的方法和组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241121

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250821

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260220